Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
IN8bio logo — Developing Next-Generation Gamma-Delta T Cell Engagers and C...

IN8bio

Developing Next-Generation Gamma-Delta T Cell Engagers and Cellular Therapies for Cancer & Autoimmune Disease

Founded 2016 United States New York, United States 25 employees Unknown Total: $209.96M Biotechnology, Health Care +2

General Information

Company Name IN8bio
Founded Year 2016
Location United States New York, United States +2
Employees 25
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Unknown
Social

Get notified when IN8bio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

IN8bio is actively securing substantial capital through recurring private placements, most recently raising over $40 million in December 2025 with institutional investor participation, demonstrating continued financial backing for its clinical programs. Concurrently, the company is maintaining strong scientific visibility by planning a poster presentation at ASCO26 in June 2026, showcasing ongoing advancements in its gamma-delta T cell therapies. These efforts underscore a strategic dual focus on funding long-term clinical development and enhancing its profile within the oncology community.

Signal Types
Funding Event Participation Clinical Development
Strategic Labels
Capital Mobilization Clinical Advancement Scientific Outreach
Next Move: Clinical Trials
·
Impact: 8/10
·
Ideal For: Biotech Investors — Clinical Stage

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. The company leverages its expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific manufacturing capabilities through its DeltEx platform to develop ex vivo-expanded and activated gamma-delta T cells. This approach, which includes allogeneic, autologous, and genetically modified techniques, aims to effectively identify and eradicate tumor cells. Founded in 2016 and headquartered in the United States, IN8bio is currently the most clinically advanced gamma-delta T cell company and the first to introduce genetically modified gamma-delta T cells into the clinic. The company's innovative gamma-delta T cell therapies represent a progressive step in cancer treatment, targeting the innate and adaptive immune systems to differentiate between healthy and diseased tissue. For further information about IN8bio and its programs, interested parties can visit www.IN8bio.com. This biotechnology startup presents a promising investment prospect in the health care and wellness industry, with a focused mission on advancing cancer treatments through cutting-edge cellular therapies.

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Private Placement Non Vc •••••• 2
Investor Investor
01 Dec 2025
Private Placement Non Vc •••••• - 01 Oct 2024
Private Placement Non Vc •••••• - 01 Dec 2023
Post Ipo Equity •••••• - 01 Aug 2022
IPO •••••• - 01 Jul 2021

View All 8 Funding Rounds

IN8bio Alternatives & Competitors

IN8bio vs
Acepodia
Acepodia United States

POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER

Series D
49 employees
Biotechnology, Health Care
Compare IN8bio vs Acepodia
IN8bio vs
LAVA Therapeutics N.V.
LAVA Therapeutics N.V. The Netherlands

Developing next generation bispecific gamma-delta T cell engaging (bsTCE) antibodies to fight cancer

Series C
7 employees
Biotechnology, Life Sciences
Compare IN8bio vs LAVA Therapeutics N.V.
IN8bio vs
Marker Therapeutics, Inc.
Marker Therapeutics, Inc. United States

Pioneering a Multi-Antigen Approach

Grant
20 employees
Biotechnology, Health and Wellness
Compare IN8bio vs Marker Therapeutics, Inc.

FAQ About IN8bio

Developing Next-Generation Gamma-Delta T Cell Engagers and Cellular Therapies for Cancer & Autoimmune Disease
IN8bio was founded in 2016.
IN8bio is headquartered in New York, United States.
IN8bio operates in the following industries: Biotechnology, Health Care, Health and Wellness, Pharmaceutical.
IN8bio has approximately 25 employees.
IN8bio has completed 8 funding rounds, raising a total of $209.96M. The latest funding stage is Unknown.
Top alternatives and competitors to IN8bio include Acepodia, LAVA Therapeutics N.V., Marker Therapeutics, Inc., Luminary Therapeutics, Inc, Kiromic Biopharma, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
IN8bio and Acepodia are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors IN8bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy